Notably, DNMT1 silencing has been shown to increase Bax expression while decreasing Bcl‐2 and CCND1/2 in AN3CA cells, suggesting the potential of DNMT1 in endometrial carcinoma (EC) therapy [10]. This evidence concerns the gene DNMT1 and endometrial carcinoma.